Esophageal Cancer Clinical Trial

Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients

Summary

Hypoxia is a key factor in malignant progression of a neoplasm. It is our aim to explore the basis for quantitative in vivo tumor imaging by Cu-61 diacetyl-bis(N4-methylthiosemicarbazone)PET imaging as a surrogate of tissue hypoxia. We hypothesize that the hypoxia levels are predictive of the tumor response to therapy. Patients will have 2 CU-ATSM PET scans done and the goal is to show spatially stable tracer distributions that correlate with tumor hypoxia. This study will serve as a pilot study for a PO1 submission

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Able to tolerated a PET/CT scan
Age 18 or older
Patient being considered for XRT for treatment of their cancer
Able to provide written informed consent

Exclusion Criteria:

severe claustrophobia or inability to tolerate the PET scan
pregnant or breastfeeding women
Patients that need supplemental oxygen
Patients enrolled in experimental treatments

Study is for people with:

Esophageal Cancer

Estimated Enrollment:

9

Study ID:

NCT00585117

Recruitment Status:

Terminated

Sponsor:

University of Wisconsin, Madison

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Wisconsin Hospital and Clinics
Madison Wisconsin, 53792, United States

How clear is this clinincal trial information?

Study is for people with:

Esophageal Cancer

Estimated Enrollment:

9

Study ID:

NCT00585117

Recruitment Status:

Terminated

Sponsor:


University of Wisconsin, Madison

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider